基质金属蛋白酶 9 mRNA：急性脑卒中患者的早期预后标志物。
Matrix metalloproteinase 9 mRNA: an early prognostic marker for patients with acute stroke.
机构信息
Accident and Emergency Medicine Academic Unit, The Chinese University of Hong Kong, Main Clinical Block and Trauma Centre, Prince of Wales Hospital, Shatin, NT, Hong Kong SAR.
出版信息
Clin Biochem. 2012 Mar;45(4-5):352-5. doi: 10.1016/j.clinbiochem.2011.12.006. Epub 2011 Dec 19.
OBJECTIVES
To investigate matrix metalloproteinase 9 (MMP9) mRNA as a prognostic marker in stroke.
DESIGN AND METHODS
MMP9 mRNA concentrations in 126 stroke patients were analyzed using quantitative reverse transcription-polymerase chain reaction.
RESULTS
The normalized MMP9 mRNA concentration was almost 3 times higher in non-survival patients compared to survival patients (P=0.0002); and 1.9-fold higher in patients with post-stroke modified Rankin score (mRS) >2 than patients with mRS≤2 (P<0.05).
CONCLUSIONS
MMP9 mRNA was a predictor of poor outcome and mortality in stroke.
目的
研究基质金属蛋白酶 9（MMP9）mRNA 作为卒中的预后标志物。
设计与方法
采用定量逆转录聚合酶链反应分析 126 例卒中患者的 MMP9 mRNA 浓度。
结果
与存活患者相比，非存活患者的 MMP9 mRNA 浓度归一化值几乎高出 3 倍（P=0.0002）；与改良 Rankin 量表（mRS）评分≤2 的患者相比，mRS>2 的患者 MMP9 mRNA 浓度高 1.9 倍（P<0.05）。
结论
MMP9 mRNA 是卒中不良预后和死亡的预测指标。
Zotero 插件